Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at Two Upcoming November Investor Conferences

BOTHELL, Wash., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
November 05, 2018 16:08 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Third Quarter 2018 Financial and Operating Results

- Biologics License Application (BLA) submission on track for Q1 2019 - - Robust manufacturing package for BLA submission to include positive results from pharmacokinetic comparability study - -...
October 29, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

BOTHELL, Wash., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
October 23, 2018 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab

BOTHELL, Wash., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Alder Biopharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
October 05, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
September 28, 2018 16:05 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
September 14, 2018 17:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash., Sept. 14, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
August 30, 2018 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences

BOTHELL, Wash., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...
August 07, 2018 16:07 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® Reports Second Quarter 2018 Financial and Operating Results

- Presented new eptinezumab Phase 3 clinical trial data in episodic and chronic migraine demonstrating robust efficacy that is sustained and further improved after repeat quarterly treatments - -...
August 02, 2018 08:00 ET | Source: Alder BioPharmaceuticals, Inc.

Alder BioPharmaceuticals® to Present at the Canaccord Genuity 38th Annual Growth Conference

BOTHELL, Wash., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of...